Whole Blood, Components, and Fluids: The Choices Inside the Program
For a civilian prehospital blood transfusion program, product choice is a decision about more than what a patient receives. It is also a decision about what an EMS crew can carry, warm, verify, administer, replace, and explain to a receiving hospital. This chapter compares whole blood, packed red blood cells (PRBC), plasma, and crystalloid fluids using the same questions: what does the option contribute physiologically, what burden does it create for the program, and how certain is the evidence that it improves patient outcomes?
What each option solves—and what it asks the system to solve
Severe bleeding creates several problems at once. The patient loses circulating volume, red cells that carry oxygen, and components that help form and stabilize clots. The options used in prehospital resuscitation address those problems in different combinations. None should be treated as a generic synonym for “fluid,” and none can be evaluated only by looking at the contents of a bag.
Whole blood packages the major blood components together. Its attraction is straightforward: a single product can provide red cells for oxygen delivery along with plasma and other coagulation-related components. In a fast-moving emergency, that can reduce the number of separate products a crew must identify and assemble. The benefit is partly physiologic and partly administrative. Fewer product decisions may simplify the act of transfusion when attention is divided among hemorrhage control, access, monitoring, and transport.
The same packaging creates a supply problem. Whole blood can be harder to obtain, sensitive to fluctuations in availability, and difficult to justify if demand is too variable. Its usable life may be shorter than that of some separated products. A unit that is not transfused can become waste unless the program has a reliable process for returning it to a blood bank or trauma center. Partners may also be more cautious about whole blood because they must agree on sourcing, liability, documentation, and the population the program will serve. Whole blood can make administration simpler at the patient’s side while making stewardship more demanding at the system’s side.
PRBC concentrates the red-cell part of the intervention. Its clearest physiologic contribution is oxygen-carrying capacity, but it does not by itself provide the same combination of coagulation support as whole blood. A program can pair PRBC with plasma or other products when its protocol calls for component therapy. That separation gives an EMS system flexibility: products can be used independently, combinations can be adjusted, and inventory can be aligned with what a blood bank already supplies.
Flexibility is not free. Component therapy may require more preparation, more product identification, more equipment, or more coordination between the crew and the receiving facility. The program must keep track of which products were given and how they fit together. It must also make sure that an option that appears available in inventory can be delivered within the time and temperature constraints of the call. The clinical question is not simply whether PRBC contains the needed red cells. It is whether the whole component pathway can reach the patient without creating a delay or an avoidable error.
Plasma contributes proteins and coagulation factors rather than the oxygen-carrying red cells supplied by PRBC. In the reviewed studies, plasma took several forms, including thawed plasma, frozen plasma rapidly thawed before transfusion, and lyophilized plasma. Those forms are not operationally identical. Thawed or frozen products place demands on cold storage and warming or thawing; lyophilized plasma can offer different shelf-stability and preparation characteristics, although availability depends on setting and regulation. A program comparing “plasma” therefore has to ask which form was used, how it was stored, and what other products accompanied it.
Plasma can also change the volume strategy. Some studies found less crystalloid use when plasma was given, while others found no difference in fluid or blood-product requirements. That variation is a reminder that the effect of a product depends on the treatment pathway around it. Plasma alone, plasma with PRBC, plasma versus crystalloid, and plasma delivered as part of a broader strategy are distinct comparisons.
Crystalloid fluids replace circulating volume but do not carry oxygen or supply the same clotting components as blood. They remain an important fallback when blood products are unavailable, delayed, or outside a system’s capability. Their weakness is not that they have no role; it is that volume replacement alone cannot replace every function lost through hemorrhage. Large volumes can dilute blood components and are associated in some studies with coagulopathy, acute respiratory distress syndrome, or a greater need for later blood products. Other studies did not find the same harms, so the concern supports a bounded, context-sensitive strategy rather than a universal prohibition.
These differences create a common comparison frame. At the patient level, ask whether the option supplies volume, oxygen-carrying red cells, coagulation support, or some combination. At the crew level, ask how many steps, products, access points, warming requirements, and monitoring tasks are involved. At the program level, ask whether the inventory can be sourced, kept within temperature limits, rotated, returned, and audited. At the evidence level, ask whether the option was compared directly with a meaningful alternative in patients like those the program will treat.
The resulting trade-off is easy to state but hard to resolve: whole blood may simplify emergency administration but constrain supply; components may increase flexibility but add coordination; plasma may support clotting but create thawing and storage demands; crystalloid may be widely available but lack oxygen and clotting support. These are not abstract features. They determine how quickly a program can act, how much it wastes, and how confidently it can explain its decisions.
The diagram deliberately ends in a conditional choice rather than a winner. It places physiology and logistics beside evidence uncertainty because a blood program cannot remove one dimension from the others.
Why the outcome evidence does not crown one product
The AHRQ review’s product findings become more coherent when read through that frame. Whole blood was evaluated in four retrospective comparative studies involving 4,623 patients. Two studies compared it with no prehospital transfusion or crystalloid and suggested lower mortality rates; two compared it with blood products or component therapy and suggested higher mortality. None of those directions produced a statistically reliable conclusion. The studies were likely underpowered, two used potentially overlapping registry populations, and the groups differed at baseline. The review therefore rated the mortality strength of evidence as insufficient.
That finding does not cancel whole blood’s rationale. It limits what can be claimed about its comparative effect. The evidence supports saying that whole blood can combine red-cell and coagulation support and may simplify administration. It does not support saying that whole blood is safer or more effective than component therapy for every civilian prehospital patient. A program may still select it because its local supply partnership, equipment, clinician training, and transport pattern make it workable. That is a feasibility judgment, not a mortality ranking.
PRBC has a larger observational evidence base. Eight nonrandomized studies involving 3,466 patients reported no significant mortality difference when PRBC was compared with usual care or active interventions. The review rated some discharge comparisons at moderate strength and most 24-hour and 30-day comparisons at low strength. The results varied with the comparator and the combination around PRBC. In some studies it was paired with crystalloid; in others with tranexamic acid or plasma; in still others the comparison reflected what patients actually received rather than what they had been assigned to receive.
The practical implication is that “PRBC versus usual care” is not one stable intervention. Usual care differs by system, and a PRBC group may have been selected because clinicians recognized greater severity or because a particular transport service was available. Harms were also incompletely reported. Coagulopathy appeared frequently in studies that measured it, and one comparison found it more often with PRBC than with leukocyte-depleted blood. No eligible studies in that question reported morbidity outcomes. The evidence supports continued use where a program can govern it, but not a claim that more studies of PRBC have established superiority.
Plasma shows a different form of uncertainty. Two randomized trials found no clear mortality effect when plasma was compared with crystalloid within 24 hours or up to 30 days, with confidence intervals wide enough to include meaningful benefit or harm. Several secondary analyses of the PAMPer trial suggested better survival with thawed plasma in selected groups, including patients transported directly from the scene, patients with traumatic brain injury in one analysis, or patients meeting particular hemorrhage thresholds. Those findings are clinically interesting, but secondary analyses can differ from the randomized parent comparison, and multiple publications may share patients. The review rated plasma versus usual care as low strength of evidence and plasma versus active interventions as insufficient.
Crystalloid findings are shaped by volume and comparator. Pooled analyses sometimes favored lower volumes for 24-hour mortality, but the evidence was insufficient and 30-day mortality showed no clear difference. When crystalloid was compared with PRBC, pooled 30-day mortality showed no difference with low strength of evidence, while 24-hour results were inconsistent. Comparisons with plasma were also inconclusive. Several studies associated higher crystalloid exposure with greater later transfusion requirements; some reported associations with acute respiratory distress syndrome or mortality, while other studies found no difference. The review supports concern about dilution and downstream resource use, but it does not establish one volume boundary that applies to every patient, injury, transport time, or EMS system.
The 2025 civilian coalition guideline is more specific operationally. It recommends hemostatic resuscitation when indicated, lists whole blood, plasma, and PRBC as options, and advises minimizing crystalloid, including a recommendation to limit crystalloid resuscitation to less than 500 mL. That threshold belongs to the guideline’s practice framework. It should not be presented as a mortality estimate that the AHRQ review has proved. The guideline’s role is to give a program a controlled way to act; the review’s role is to describe how confidently outcome claims can be made.
This distinction leaves room for more than a binary choice. A system may build a component-based program first because its blood bank already supports PRBC and plasma, then consider whole blood after it has demonstrated reliable storage, training, and case review. Another system may use an intercept model, keeping products centrally and moving them to the scene, rather than carrying the same inventory on every vehicle. A rural service may face a different balance between availability, transport distance, and waste than an urban service. These examples do not prove which product is clinically best. They show why program architecture can make one option more deliverable than another.
A defensible comparison therefore asks whether the program can meet five conditions at once: an appropriate clinical indication, a product available soon enough to matter, intact storage and warming controls, clinicians and medical oversight capable of safe administration, and transport and handoff that preserve continuity. If those conditions cannot be met, forcing a preferred product into the system can convert theoretical benefit into delay, error, or waste. If they can be met, operating the program still does not settle the mortality question; it creates an opportunity to collect better evidence.
The unresolved choice is not a failure of analysis. It is the actual state of the field. Whole blood, components, plasma, and crystalloid each expose a different boundary between physiology and operations. The next issue is what happens when those options are combined with adjuncts and delivered against the clock, because the strongest mortality signal in the review belongs to a coordinated strategy rather than to a product considered alone.